News

Latest Press Releases

August 4, 2022

AnHeart Therapeutics to Present Poster and Host Investigator Meeting at WCLC 2022

August 3, 2022

AnHeart Therapeutics Receives FDA Breakthrough Therapy Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

August 1, 2022

AnHeart Therapeutics Appoints Dr. Shuanglian (Lian) Li as Chief Medical Officer (US)

June 6, 2022

AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1 Inhibitor) at ASCO 2022

More Press Releases

Latest News Articles

March 21, 2022
MedCity News

Precision oncology startup AnHeart Therapeutics co-founder shares cancer drug strategy

January, 10-12, 2022
Biotech Showcase

Outsmarting Cancer: Next Generation Therapies

December 16, 2021
Bioworld

Anheart Therapeutics raises $61M in series B for precision oncology pipeline

More News Articles

Media Contact

Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com